Satsuma Pharmaceuticals, Inc.
Information
Satsuma is a clinical-stage biopharmaceutical company developing a novel therapeutic product for the acute treatment of migraine, STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate.